Your browser is no longer supported. Please, upgrade your browser.
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
Index- P/E59.40 EPS (ttm)3.08 Insider Own0.34% Shs Outstand221.02M Perf Week-1.93%
Market Cap40.45B Forward P/E12.86 EPS next Y14.23 Insider Trans0.00% Shs Float220.09M Perf Month1.30%
Income- PEG7.00 EPS next Q3.33 Inst Own88.27% Short Float3.84% Perf Quarter8.64%
Sales6.26B P/S6.46 EPS this Y7.80% Inst Trans- Short Ratio2.12 Perf Half Y16.01%
Book/sh56.21 P/B3.26 EPS next Y5.50% ROA- Target Price177.36 Perf Year71.01%
Cash/sh- P/C- EPS next 5Y8.49% ROE- 52W Range99.91 - 187.45 Perf YTD17.13%
Dividend- P/FCF- EPS past 5Y17.70% ROI- 52W High-2.37% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low83.16% ATR2.14
Employees3837 Current Ratio- Sales Q/Q13.30% Oper. Margin- RSI (14)53.56 Volatility1.24% 1.03%
OptionableNo Debt/Eq- EPS Q/Q14.10% Profit Margin- Rel Volume0.00 Prev Close183.00
ShortableNo LT Debt/Eq- EarningsApr 30 BMO Payout- Avg Volume3.99M Price183.00
Recom2.70 SMA20-0.20% SMA501.80% SMA20018.76% Volume0 Change0.00%
May-05-21Upgrade Oppenheimer Perform → Outperform $205
Apr-26-21Resumed Credit Suisse Neutral $190
Mar-23-21Downgrade SVB Leerink Outperform → Mkt Perform
Dec-16-20Downgrade Truist Buy → Hold $175
Dec-14-20Downgrade Wedbush Outperform → Neutral $175
Dec-14-20Downgrade Robert W. Baird Outperform → Neutral $175
Dec-14-20Downgrade Credit Suisse Outperform → Neutral $147 → $194
Dec-14-20Downgrade BMO Capital Markets Outperform → Market Perform $152 → $175
Oct-28-20Initiated UBS Neutral $133
Sep-01-20Resumed Stifel Hold $120 → $117
Jul-31-20Downgrade William Blair Outperform → Mkt Perform
Apr-28-20Initiated Cantor Fitzgerald Neutral $121
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
Jul-23-21 03:12PM  
Jul-22-21 03:03PM  
Jul-21-21 11:40AM  
Jul-17-21 07:01AM  
06:48AM  
Jul-16-21 01:54PM  
10:17AM  
07:29AM  
02:01AM  
Jul-15-21 07:01PM  
04:05PM  
09:19AM  
Jul-14-21 08:00PM  
12:45PM  
09:45AM  
02:55AM  
Jul-13-21 10:21AM  
09:15AM  
01:36AM  
Jul-06-21 12:08PM  
10:16AM  
06:27AM  
Jul-05-21 11:40AM  
Jun-16-21 12:42PM  
Jun-14-21 02:07PM  
Jun-11-21 03:01AM  
Jun-09-21 03:53PM  
Jun-08-21 12:05PM  
Jun-07-21 01:55PM  
May-25-21 07:54AM  
07:24AM  
May-19-21 02:38AM  
May-17-21 10:12AM  
May-12-21 04:14PM  
04:01PM  
07:55AM  
May-11-21 09:28AM  
May-10-21 08:51AM  
May-06-21 06:00PM  
May-03-21 09:33AM  
Apr-30-21 12:25PM  
10:28AM  
08:00AM  
Apr-28-21 05:00PM  
Apr-26-21 12:31PM  
09:42AM  
Apr-22-21 12:47PM  
Apr-21-21 08:20AM  
Apr-20-21 08:00AM  
Apr-19-21 02:34PM  
10:05AM  
08:36AM  
Apr-16-21 09:40PM  
10:13AM  
06:53AM  
Apr-12-21 01:17AM  
Apr-07-21 11:54AM  
Apr-06-21 11:50AM  
Apr-05-21 08:31PM  
Mar-30-21 08:18AM  
Mar-29-21 07:05PM  
Mar-26-21 02:08PM  
Mar-25-21 02:17PM  
Mar-20-21 03:11PM  
12:34PM  
Mar-19-21 09:45PM  
03:36PM  
Mar-17-21 08:22AM  
Mar-16-21 04:31PM  
Mar-13-21 01:32PM  
Mar-12-21 03:10PM  
Mar-10-21 11:17AM  
Mar-09-21 05:02PM  
Mar-06-21 11:31AM  
Mar-05-21 06:45PM  
07:00AM  
Mar-04-21 04:56PM  
Mar-01-21 12:04PM  
11:08AM  
08:00AM  
Feb-26-21 02:40PM  
Feb-22-21 08:33AM  
Feb-20-21 02:11PM  
Feb-19-21 04:15PM  
Feb-13-21 12:06PM  
Feb-12-21 12:12PM  
Feb-11-21 11:40AM  
10:30AM  
09:59AM  
07:57AM  
Feb-10-21 08:56AM  
Feb-06-21 11:52AM  
Feb-05-21 03:16PM  
02:06PM  
Feb-04-21 11:48AM  
09:25AM  
08:00AM  
Feb-03-21 08:43AM  
07:12AM  
Feb-02-21 10:00AM  
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bazarko DanielSVP, Controller, CAODec 17Option Exercise117.0424,0662,816,74054,949Dec 21 05:00 PM
Bazarko DanielSVP, Controller, CAODec 17Sale157.7024,0663,795,23330,883Dec 21 05:00 PM
Carino TanishaEVP & CCAODec 03Sale122.261,530187,05816,102Dec 04 04:47 PM